YIDU TECH (02158) surged over 5% in afternoon trading. As of press time, the stock was up 4.23% to HK$6.65, with a trading volume of HK$69.4676 million.

On the news front, on August 12, the "Vascular Disease Multimodal Specialty Database" and "Mei Yi AI Agent" jointly developed by YIDU TECH and Guangdong Medical University Affiliated Hospital were officially unveiled at the 2025 Academic Annual Conference of the Plastic and Aesthetic Surgery Professional Committee of Guangdong Hospital Association.

The "Mei Yi AI Agent," serving as the core technology carrier, was co-developed by YIDU TECH and the plastic surgery department of Guangdong Medical University Affiliated Hospital. It transforms data value into clinical applications and represents YIDU TECH's first implementation of large models in the medical aesthetics field.

Additionally, at the recently held 2025 Digital Therapeutics Conference, YIDU TECH participated as an AI medical enterprise deeply involved in Hainan's "2+3" diabetes management project and announced its "report card" for implementing digital therapeutics in Hainan. Since launching the pilot program in 2023, YIDU TECH has closely collaborated with Lingshui County to address issues such as doctor-patient connectivity.

Currently, 99.09% of managed patients in Lingshui County have been incorporated into systematic care. The fasting blood glucose target achievement rate and glycated hemoglobin target achievement rate have improved by 18.63% and 4.68% respectively from baseline levels, significantly exceeding the provincial average.

Following Lingshui, the company will gradually extend its AI medical innovation achievements to cities including Sanya, Wanning, Qionghai, and Wenchang. The company plans to expand digital therapeutics services to cover more chronic diseases such as hypertension, and expects to achieve coverage management of over 100,000 regional patients within 2025.